PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Clinical Cancer Research

Abstract PS3-11-07: Real-world use of neratinib in her2-positive early breast cancer in korea: updated follow-up from a multicenter observational study

View Full Paper
Ask AI
Bookmark
Share

Authors

SKS. KimSKS. KimKSK. Shin

Discussion

Loading...

Member takes

Overview

This multicenter observational study reports outcomes of neratinib in early breast cancer, indicating treatment feasibility and tolerability.

Key Points

  • The study aims to evaluate the real-world use and outcomes of neratinib in patients with HER2-positive early breast cancer post-trastuzumab therapy.
  • Retrospective analysis of 48 HR+/HER2+ early breast cancer patients
  • Neratinib treatment initiated following trastuzumab-based therapy
  • Adverse events and disease recurrence data collected
  • Primary endpoint focused on treatment pattern and tolerability
  • No invasive disease recurrence was observed during the median 11.8 months of follow-up
  • Most patients tolerated neratinib well with appropriate diarrhea prophylaxis
  • Diarrhea emerged as the most common treatment-emergent adverse event (88.6%)
  • Grade ≥3 toxicities occurred in 12.5% of patients
  • 31 out of 48 patients completed the full one-year course of neratinib

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/6996a869ecb39a600b3ef122https://doi.org/10.1158/1557-3265.sabcs25-ps3-11-07
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PO1-17-08: Post-approval treatment patterns and tolerability of neratinib in HER2+ early-stage breast cancer2024
  2. 2Abstract PS3-11-21: A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: interim results from the NERLYFE study2026 · 1 citations
  3. 3Abstract PO1-01-06: Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer2024
  4. 4119P HER2+ early-stage breast cancer treated with extended adjuvant neratinib in the context of the European Early Access Program: NEAR study final results2024
  5. 5Abstract PS3-10-29: Ner-tree study interim analysis of safety and patient-reported outcomes in patients with human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (eBC) treated with neratinib in China2026